Product Description
| Download Documents | |
| Product Sheet | |
| SDS | COA_Lot#072420 |
MMAE (monomethyl auristatin E) is an antimitotic agent that binds to tubulin and inhibits the assembly of microtubules. Mc-VC-PAB-MMAE is a thiol reactive derivative of MMAE that contains a cathepsin cleavable valine-citruline p-aminobenzylcarbamate linkage. Mc-VC-PAB-MMAE is used to prepare antibody-drug conjugates, such as brentuximab vedotin (Seattle Genetics). This BSA-MMAE conjugate is designed with similar linker chemistry as ADCs synthesized at CellMosaic® for our customers' usage in immunization or immunoassay. Thiol functional groups are introduced to the BSA followed by reaction of the maleimide group of Mc-VC-PAB-MMAE to form the conjugate.
The final conjugate is lyophilized from phosphate buffered saline containing sugar-based stabilizer for easy shipping and storage.
The product is sold as 1 vial of 1 mg (Cat# CM52113-1MG) or 5 vials of 1 mg (Cat# CM52113-5MG). For bulk orders, please contact us for a quote.
Chemical Information
- Chemical name: BSA-MMAE (monomethyl auristatin E) Conjugate
- Chemical formula: N/A
- Molecular weight: ~71KDa CAS number: N/A
Specification
- Physical appearance: white to off-white preservative-free lyophilized powder in a 2.0 mL centrifuge tube
- Storage temp.:≤-20°C for lyophilized powder. After reconstitution, the stock solution can be used up to 1 week if stored at 2-8°C.
- Purity: ≥ 99% of conjugates by HPLC
- Drug over BSA ratio: ~4 by MALDI-TOF MS (current batch)
